Showing results (201-210 of 2,810) with videos related to
Sort By:
Pageof 281
Expert Opinion on Drug Safety|July 28, 2016
Safety profile of methotrexate in inflammatory bowel diseaseTommaso Gabbani, Simona Deiana, Sarah Lunardi, et al.Expert Opinion on Drug Safety|June 20, 2020
Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trialsHirotaka Watada, Toshimasa Yamauchi, Fumiko Yamamoto, et al.Expert Opinion on Drug Safety|May 28, 2020
Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinomaAntoine Desilets, Denis SoulièresExpert Opinion on Drug Safety|September 8, 2021
Adverse reactions related to proton pump inhibitors in pediatric population: an analysis of spontaneous reporting dataValeria Dipasquale, Giuseppe Cicala, Francesca Laganà, et al.Expert Opinion on Drug Safety|May 17, 2021
Antimicrobial resistance and the post antibiotic era: better late than never effortPrashant Chandra, Unnikrishnan Mk, Vandana Ke, et al.Expert Opinion on Drug Safety|August 2, 2022
Pharmacovigilance regulatory actions by national pharmacovigilance centers in Arab countries following COVID-19 pandemicSameh A Al-Zubiedi, Manal Younus, Sara Al-Khalidi, et al.Expert Opinion on Drug Safety|August 4, 2022
Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non-small cell lung cancer: an observational, retrospective, pharmacovigilance studyZhuo Ma, Jie Pei, Yi Zhang, et al.Expert Opinion on Drug Safety|August 23, 2022
Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysisJohn Hang Leung, Yun-Sheng Tai, Shyh-Yau Wang, et al.Expert Opinion on Drug Safety|August 5, 2022
Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance studyJunyan Wu, Jianxiang Huang, Jianhong Zhu, et al.Expert Opinion on Drug Safety|August 10, 2022
Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs)Merel de Boer, Helen R Gosselt, Jurriaan Jansen, et al.Pageof 281